Boston, MA -- The Johns Hopkins University School of Medicine today announced plans to offer three major cardiology summits on its interactive, live platform, CardioCareLive, the world’s largest live online cardiology congress. These complimentary Continuing Medical Education (CME) Summits to be held over two days on Tuesday June 28th and Wednesday June 29th and will focus on topics of interest to cardiovascular care and internal medicine and family care physicians in Atrial Fibrillation, Interventional Cardiology and Lipids. The Atrial Fibrillation Summit at CardioCareLive is supported by educational grants from Bristol-Myers Squibb and Pfizer, Inc. and Boehringer Ingelheim, the Interventional Cardiology Summit is supported by an educational grant from Daiichi/Lilly and the Lipids Summit at CardioCareLive is supported by an educational grant from Merck & Co.

The Cardiovascular Research Foundation is joining Johns Hopkins in presenting the four sessions within the Interventional Cardiology Summit beginning at 2:00 PM EDT on Tuesday June 28th. The Cardiovascular Research Foundation’s mission is to improve the survival and quality of life for people with cardiovascular disease through research and education.

CardioCareLive enables physicians, nurse practitioners and physician assistants and other healthcare practitioners to stay current on advances in cardiovascular care at no cost by viewing streaming video CME presentations featuring recognized cardiology experts from the convenience of any computer. A total of 12 AMA PRA Category I Credits™ will be available during the live programming June 28th and June 29th in addition to the 13 AMA PRA Category I Credits™ currently available on demand in enduring format at CardioCareLive. There is no charge to register and attend any program at CardioCareLive.

Physicians from the nation’s most respected teaching hospitals and cardiology care associations will act as activity directors for the three programs over two days at CardioCareLive. Dr. Roger Blumenthal, Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, will be the Activity Director for the Atrial Fibrillation, Interventional Cardiology and Lipids Summits. He will be joined by Dr. Gregg Stone, Professor of Medicine at Columbia University College of Physicians and Surgeons, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, and Co-Director of the Medical Research and Education Division at the Cardiovascular Research Foundation, as activity director for the Interventional Cardiology summit. Dr. Chris Cannon, Associate Professor of Medicine at Harvard Medical School and Associate Physician, Cardiovascular Division at Brigham and Women's Hospital, will join Dr. Roger Blumenthal as Activity Director for the Atrial Fibrillation and Lipids summits.

Live programming begins on Tuesday June 28th at 9:00 AM EDT and again on Wednesday June 29th at 11:00 AM EDT, with individual presentations beginning on the hour. Practitioners who attend live may take advantage of interactive capabilities by texting in questions to be addressed live -online by presenting faculty. Each session will be available in on demand (enduring) format as soon as the session concludes. The agenda features the following topics:

ATRIAL FIBRILLATION
Are We Getting Better at Identifying AF Patients at High Risk of Stroke?
Stroke Prevention in AF: Putting the Current Guidelines Into Clinical Practice
New Frontiers in Stroke Prevention in the AF Setting: A Focus on Unmet Patients’ Needs
Optimizing Therapy Choices to Prevent Stroke in Patients With AF

INTERVENTIONAL CARDIOLOGY
In partnership with the Cardiovascular Research Foundation
Clinical Perspectives in Stent Thrombosis: A Focus on Prevention and Management
Optimizing Performance Measures to Improve STEMI Outcomes Syndromes
Who Is at Risk of Antiplatelet Resistance: From Genetics to Clinical Relevance
Stents in Patients With Stable Angina: Overused or Misunderstood?

LIPIDS
Optimizing Current Strategies with Statins: A Focus on New Evidence
Moving Beyond Statin Treatment in Dyslipidemias
Emerging Therapies and Their Role in Comprehensive Lipid Management
Management of Residual Cardiovascular Risk
To learn more about supporting these and other educational programs, please contact info@CardioCareLive.com.

Source: Cardio Care